We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$1B
AUM Growth
+$157M
Cap. Flow
-$40.2M
Cap. Flow %
-4.01%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$26M
2
HRMY icon
Harmony Biosciences
HRMY
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$716M 71.37%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$117M 11.7%
3,063,194
-441,430
-13% -$14.2M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$49.2M 4.9%
2,200,778
– –
PHVS icon
4
Pharvaris
PHVS
$2.48B
$40.8M 4.07%
2,303,310
– –
IMPL
5
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$33.6M 3.35%
2,759,791
– –
ELEV
6
DELISTED
Elevation Oncology
ELEV
$20.3M 2.02%
2,608,167
– –
CMPI
7
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$14.6M 1.45%
3,673,374
– –
MTCR
8
DELISTED
Metacrine, Inc. Common Stock
MTCR
$10.5M 1.05%
3,059,123
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$887K 0.09%
161,897
– –
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
– –
-411,471
Closed -$26M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q3 2021 Portfolio in Review

As of Q3 2021, venBio Partners held 10 positions worth $1B, up 18% from $847M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $40.2M in Q3 2021, closing 1 position and reducing 1 holding. Its most notable exit was Apellis Pharmaceuticals, an estimated $26M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q3 2021 reduction was Harmony Biosciences, cutting an estimated $14.2M.
  • venBio Partners fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $26M.
  • venBio Partners's ten largest holdings make up 100% of its $1B portfolio in Q3 2021.
  • venBio Partners opened 0 new positions and closed 1 in Q3 2021.
  • venBio Partners's portfolio value rose 18% quarter-over-quarter to $1B.

Based on venBio Partners's 13F filing for Q3 2021, filed 15 Nov 2021.